PRNewsWire
02 Sept 2026, 17:40 UTC · 6w ago
Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
Impact · against what's priced in
Soleno Therapeutics faces significant downside risk due to allegations of concealed safety data (fluid retention) in its Phase 3 DCCR trials, which threatens both regulatory approval and commercial viability. Geron Corporation is mentioned in a separate, brief investigation notice from the same law firm, representing a smaller but negative legal headwind.
- SLNO−0.80
No priced-in read yet





